Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection
Дата публикации: 22-06-2026 07:06:00




Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
2Blood test may help identify which colorectal cancer patients most likely to benefit from chemotherapy after surgery0506-07-2026
3Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery0703-07-2026
4Hidden metastases reveal clues to colorectal cancer recurrence3709-07-2026
5Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma0509-07-2026
6Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma5730-06-2026
7Prédiction de la réponse thérapeutique du cancer du rein par l’analyse des réseaux de gènes0715-09-2025
8Precision therapy for metastatic prostate cancer improves survival2720-08-2024
9Выявлены ключевые маркеры для оптимизации индивидуальной терапии рака желудка0005-06-2025
10Blood test distinguishes neuroendocrine subtype of advanced prostate cancer0810-01-2024

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.esmo.org.